Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive WM

Key Findings

• ●Novel fixed-duration combination of ibrutinib + venetoclax in treatment-naive WM
• ●Aims to achieve deep responses with time-limited therapy
• ●Represents shift toward combination approaches

Referenced in (1 disease)